News
Eli Lilly (LLY 1.15%) and Novo Nordisk (NVO 0.14%) are two phenomenal growth stocks that investors probably can't go wrong ...
Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the future.
Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...
The drug coverage provision does not mention any specific drug by name, but it could include the GLP-1 agonists, such as ...
Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?
Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth ...
8h
Money Talks News on MSNYour Wegovy Access Just Changed: What Patients Need to Know NowNovo Nordisk just pulled Wegovy from a major telehealth platform over safety concerns about knockoff versions. Here's what ...
The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...
Novo keeps China manufacturing investments rolling with $112M for new quality testing lab in Tianjin
A little over a year after celebrating its 30th anniversary in China with a major production upgrade, Novo Nordisk is back ...
A new study found that semaglutides like Ozempic are linked to a lower risk of Alzheimer's disease and dementia. Below, a ...
Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results